💾 Archived View for gmi.noulin.net › mobileNews › 3520.gmi captured on 2021-12-05 at 23:47:19. Gemini links have been rewritten to link to archived content
⬅️ Previous capture (2021-12-03)
-=-=-=-=-=-=-
By James Gallagher Health reporter, BBC News
A widely-used drug might help treat children with a condition that ages them up
to eight times too quickly, Durham University researchers believe.
People with progeria also suffer heart problems, lack of growth and loss of
body fat and hair.
Writing in Human Molecular Genetics, scientists said the condition was partly
down to DNA damage caused by highly reactive oxygen chemicals.
They said the drug, n-acetylcysteine, could control the damage.
The average life expectancy for someone with the condition is about 13 years.
Their cells show significant defects, which researchers put into two
categories: damage to the DNA and physical disruption of the cell's shape.
Prof Christopher Hutchinson, who led the study, said trials for drugs to
correct the shape problems were showing some success.
He has been investigating the cause of, and simple solutions to, the damage to
the genetic code.
'Very exciting'
The team at Durham University found that levels of damaging "reactive oxygen
species" were five to 10 times higher in cells of patients with accelerated
ageing.
They used n-acetylcysteine, which is already used to prevent liver damage in
patients who have overdosed on paracetamol, on cells in the laboratory.
The drug soaked up the reactive oxygen. DNA damage in the cells then returned
to "approximately normal levels".
Prof Hutchinson said: "For us it is very exciting."
However, it is unknown what the effect would be if the drug was given to
children with the illness or how it would work with other drugs.
Prof Hutchinson told the BBC: "I have to say this is one more piece in the
jigsaw which will eventually allow us generate treatments, but it is one more
piece."
A full randomised clinical trial of the drug is not possible as the condition
is so rare. The Progeria Research Foundation says there are just 78 children
known to have the condition.
Its medical director Dr Leslie Gordon said: "[Prof] Hutchison's study has not
only confirmed basic cellular defects in progeria, but has also identified
potential ways to improve those defects.
"This type of biological science is how progress towards treatments and a cure
for children with progeria will advance."
The findings might also one day have benefits for ageing in the wider
populations.
Prof Hutchinson said: "If you give a child a drug which extends lifespan
without adverse affects then you would expect these to be useful in an older
population."